References
- Torres H A, Boeckh M, Chemaly R F. Viral infections. Internal Medicine Care of Cancer Patient, 1st ed, S J Yeung, C Escalante, R F Gagel. BC Decker, in press
- García-Muñoz R, Galar A, Moreno C, Rodríguez-Otero1 P, Panizo-Morgado E, Ponz-Sarvisê M, et al. Parvovirus B19 acute infection and a reactivation of Cytomegalovirus and Herpes Virus 6 in a Chronic Myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007; 48: 2461–2464
- Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs 2007; 16: 679–687
- Seggewiss R, Lore K, Greiner E, Magnusson M K, Price D A, Douek D C, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479
- Liang Y, Roizman B. State and role of SRC family kinases in replication of herpes simplex virus 1. J Virol 2006; 80: 3349–3359
- Chu J J, Yang P L. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc Natl Acad Sci USA 2007; 104: 3520–3525